BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) was the recipient of a large growth in short interest in August. As of August 31st, there was short interest totaling 6,124,886 shares, a growth of 84.8% from the August 15th total of 3,314,382 shares. Currently, 20.3% of the company’s shares are sold short. Based on an average daily trading volume, of 7,193,434 shares, the short-interest ratio is presently 0.9 days.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioXcel Therapeutics in a research report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $11.00.
Check Out Our Latest Analysis on BTAI
Institutional Investors Weigh In On BioXcel Therapeutics
BioXcel Therapeutics Stock Up 0.3%
Shares of BTAI opened at $0.07 on Thursday. The business’s fifty day moving average is $0.65 and its 200 day moving average is $1.05. BioXcel Therapeutics has a 12-month low of $0.07 and a 12-month high of $4.29. The stock has a market cap of $2.32 million, a P/E ratio of -0.02 and a beta of 0.19.
BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.05). The business had revenue of $0.18 million for the quarter, compared to analyst estimates of $0.48 million. On average, analysts expect that BioXcel Therapeutics will post -2.7 EPS for the current year.
About BioXcel Therapeutics
BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.
BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.
Featured Stories
- Five stocks we like better than BioXcel Therapeutics
- Banc of California Bets on Short-Term Pain
- Enterprise AI to Boost Broadcom’s Software Business? What Industry Data Shows
- IonQ and NVIDIA Just Cracked a Major Quantum Computing Bottleneck
- This Gold ETF Turns a Non-Yielding Asset Into Monthly Income—But There’s a Catch
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
